NovoCure (NVCR) Share-based Compensation Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.10% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 5.54% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 5.09% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 14.70% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 5.29% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 7.15% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 13.40% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 12.36% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | 17.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.26% |
| Dec 31, 2025 | -12.70% |
| Sep 30, 2025 | 3.68% |
| Jun 30, 2025 | 0.41% |
| Mar 31, 2025 | 5.67% |
| Dec 31, 2024 | 40.98% |
| Sep 30, 2024 | 6.78% |
| Jun 30, 2024 | 4.51% |
| Mar 31, 2024 | 21.80% |
| Dec 31, 2023 | -4.90% |
| Sep 30, 2023 | 9.40% |
| Jun 30, 2023 | 20.38% |
| Mar 31, 2023 | 33.15% |
| Dec 31, 2022 | 26.54% |
| Sep 30, 2022 | 22.42% |
| Jun 30, 2022 | 23.43% |
| Mar 31, 2022 | 37.43% |
| Dec 31, 2021 | 28.16% |
| Sep 30, 2021 | 34.96% |
| Jun 30, 2021 | 39.79% |
| Mar 31, 2021 | 30.33% |
| Dec 31, 2020 | 47.20% |
| Sep 30, 2020 | 32.61% |
| Jun 30, 2020 | 35.35% |
| Mar 31, 2020 | 53.69% |
| Dec 31, 2019 | 46.00% |
| Sep 30, 2019 | 36.59% |
| Jun 30, 2019 | 34.55% |
| Mar 31, 2019 | 20.93% |
| Dec 31, 2018 | 33.34% |
| Sep 30, 2018 | 52.96% |
| Jun 30, 2018 | 57.10% |
| Mar 31, 2018 | 67.53% |
| Dec 31, 2017 | 71.05% |
| Sep 30, 2017 | 92.75% |